Journal
PSYCHO-ONCOLOGY
Volume 24, Issue 4, Pages 402-407Publisher
WILEY-BLACKWELL
DOI: 10.1002/pon.3602
Keywords
breast cancer; cognition; depression; adjuvant therapy; tamoxifen; aromatase inhibitors; hormone therapy
Ask authors/readers for more resources
Background ObjectiveBreast cancer survivors receiving hormone treatment and/or endorsing histories of receiving chemotherapy report changes in their cognitive capacity, which is often not supported by formal testing. To address these conflicting reports, this study examined survivors' applied cognitive capacity and its association with hormone treatment, depression, and selected demographics. MethodsA descriptive, correlational, cross-sectional survey design was employed. There were 357 women who completed a survey comprised of 69 questions. The survey included both investigator-developed questions and instruments from the PROMIS (R) system. ResultsThere were significant main effects for hormone therapy, race, and depression. Depression explained the largest portion of variance of the perceived decreases in cognitive function among breast cancer survivors. ConclusionsSurvivor complaints of changes in cognitive function may be a predictor for evaluating the presence of mood disorders and less a function of hormone therapy or chemotherapy history. Copyright (c) 2014 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available